Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nichi-Iko Buys Sagent To Strengthen US Biosimilars Presence

Executive Summary

Nichi-Iko Pharmaceutical Co. Ltd. will pay $736m in cash for Sagent Pharmaceuticals Inc. in a deal that will further expand the Japanese company's biosimilars business beyond Asia and diversify the US generics firm's injectable medicines portfolio.

You may also be interested in...



Teva Continues Divestitures To Close Allergan Deal With Sale To Impax

Impax will gain 15 approved generics and three pipeline assets, which will help address offset lower revenues of two of its existing top-sellers.

Data Take: Forget Teva and Mylan - Big Pharma Owns Generics

The pool at the foot of the patent cliff is a dark, dynamic vortex. Teva's imminent acquisition of Allergan's generics division just about moves the needle: but it's big pharma that dominates the off-patent drugs business these days.

Aprogen Strikes Third Global Biosimilar Deal With Nichi-Iko

South Korean biotech firm Aprogen is emerging as another notable player in the increasingly crowded biosimilar space and the company has just reached its third worldwide biosimilar deal since 2014, again with Japan’s Nichi-Iko and this time for its rituximab product.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB001571

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel